AngioSense (Cupertino, California) and Repair (Boston, Massachusetts) will jointly pursue clinical applications for sustained delivery of fibroblast growth factor (FGF) to stimulate the growth of new blood vessels in diseased hearts. Under the agreement, AngioSense will supply its needle-free, jet injection delivery systems, and Repair will provide proprietary FGF protein and fibrinogen constructs. Financial details were not disclosed. The collaboration stems from positive results from preclinical studies using the AngioSense needle-free, jet injection delivery system with Repair's FGF formulation. The research was conducted by the Beth Israel Deaconess/ Harvard Medical Center Angiogenesis Research Group. Repair is applying proprietary drug delivery technologies and angiogenic agents to develop a pipeline of biological therapeutics to treat cardiovascular disease. The company is initially developing products to treat CAD, PVD and other cardiovascular diseases. AngioSense is focused on developing surgical and cardiology-based devices for needle-free, jet-injection local drug delivery applications.
A resuscitative fluid created by the University of Pittsburgh's McGowan Center for Artificial Organ Development (Pittsburgh, Pennsylvania) will be developed for commercial use as part of an agreement with Alteon (Ramsey, New Jersey) and HemoMax (Pittsburgh, Pennsylvania), a drug development company formed by Three Rivers Medical Technologies. The fluid, also called HemoMax, has been shown in animal studies to have potential to treat severe hemorrhage, such as that seen in the trauma or emergency medicine setting. It is a plant-derived preparation intended to achieve maximal oxygen delivery to tissues deprived of a blood supply without the use of or minimal reliance on so-called oxygen carriers. Alteon will manage the preclinical development of compounds arising from the technology in return for a 15% ownership of HemoMax and the right of first negotiation to sublicense the technology at a later time. The McGowan Center is investigating the use of bioengineered organ devices for treating human illness and disease. Alteon makes pharmaceuticals for the treatment of cardiovascular and renal disease and other disorders of diabetes and aging.
Micronics (Redmond, Washington) has signed an agreement to collaborate with Honeywell in developing a microminiaturized lab-on-a-chip-based blood cell monitoring device. The development will be funded by a recently awarded, three-year $4.4 million contract from the Defense Advanced Research Projects Agency (DARPA; Washington), the central research and development organization for the Department of Defense. This new generation of lab-on-a-chip-based hematology instrument uses Micronics' ORCA (Optically Resolved Chemical and Cellular Analysis) uFluidics and MicroCytometer technology to simplify the blood analysis process, eliminating sample pre-processing and instrument calibration. Together with Honeywell's micro-laser array and microfluidic driver technology, these technologies will form the basis of a wristwatch-sized blood cell monitoring system. The companies say that the device will have great utility in battlefield medicine, as well as in home care, including the monitoring of cancer patients during their chemotherapy regimen. The miniaturized instrument is expected to be so simple to use that proficiency testing will be waived under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. This means that blood tests could be performed outside the laboratory at the patient's bedside or in a physician's office by many categories of licensed medical professionals. Micronics' technology seals the patient blood sample at the end of an assay, thereby minimizing biohazard risk. The company said the technology also dramatically reduces the amount of reagents used and waste generated. Micronics is a developer of microfluidics-based solutions for application in life science (genomics), in vitro medical diagnostics and analytical chemistry markets.
St. Jude Medical (St. Paul, Minnesota) and Cordis (Miami Lakes, Florida) and Biosense Webster (Diamond Bar, California), the latter two both Johnson & Johnson companies, reported the introduction of Alliance OneSource, a new cooperative sourcing venture related to the supply of key medical device products to major hospital centers across the country. The Alliance OneSource agreement includes such cardiovascular products and technologies from St. Jude Medical and Cordis as heart valves, pacemakers, defibrillators, stents and catheters. St. Jude Medical makes medical devices. Cordis is a broad-based supplier of products for circulatory disease management. Biosense makes minimally invasive medical sensor/mapping technology enabling physicians to assess myocardial function and determine the location of medical instruments in the body during diagnostic and interventional medical procedures.
Welch Allyn Protocol (Beaverton, Oregon), a supplier of patient monitoring technology, and Mallinckrodt (Pleasanton, California) recently reached an agreement which commits the parties to closer cooperation in integrating Nellcor pulse oximetry technology into the Welch Allyn Protocol patient monitoring product line. Welch Allyn Protocol, recognizing the strong end-user demand for the latest oximetry technology to be incorporated in their devices, will work closely with Nellcor to offer Nellcor oximetry solutions in Welch Allyn Protocol monitors as they become available. Welch Allyn Protocol makes monitoring products.